Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Cancer. 2008 Nov;44(16):2350-6. doi: 10.1016/j.ejca.2008.07.042. Epub 2008 Sep 11.

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?

Author information

  • 1Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, The Netherlands. f.eskens@erasmusmc.nl

Abstract

Bevacizumab is approved for the treatment of colorectal cancer, breast cancer, non-small cell lung cancer and renal cell cancer. Before embracing this expensive agent for many other indications, it remains critical to be aware of the evidence upon which oncologists base their day-to-day clinical practice. In this review, we address the results of clinical studies upon which bevacizumab's current use is based and discuss some future perspectives.

PMID:
18789679
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk